Simulations Plus Inc (SLP)
30.04
+2.46
(+8.92%)
USD |
NASDAQ |
Nov 21, 16:00
30.02
-0.02
(-0.07%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 602.82M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -21.41% |
| Valuation | |
| PE Ratio | 61.31 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 8.716 |
| Price to Book Value | 3.304 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.06 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 69.01% |
Profile
| Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific. |
| URL | https://www.simulations-plus.com |
| Investor Relations URL | https://www.simulations-plus.com/investorscorporate-profile/corporate-profile/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Health Care Technology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Jan. 03, 2025 (est.) |
| Last Earnings Release | Oct. 23, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jul. 29, 2024 |
Ratings
Profile
| Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific. |
| URL | https://www.simulations-plus.com |
| Investor Relations URL | https://www.simulations-plus.com/investorscorporate-profile/corporate-profile/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Health Care Technology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Jan. 03, 2025 (est.) |
| Last Earnings Release | Oct. 23, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jul. 29, 2024 |